구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Zeprumetostat | Vincristine Sulfate Liposome | Vevoctadekin | Verapamil Hydrochloride |
Overview Company | Roche / Genentech | Sun Yat-sen University | M.D. Anderson Cancer Center | Simcha Therapeutics | Bristol-Myers Squibb |
Overview Modality | ADC | CGT | ANTIBODY | CGT | ADC |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | Mature T-cell and NK-cell Lymphoma | Recurrent Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Medium | Data Confidence · Low | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | — | — | — | — |
MoA Biomarker | CD20 expression | — | — | — | — |
PK/PD Half-life | 12.2 h | — | — | — | 16 h |
PK/PD Species | Rat | — | — | — | — |
PK/PD Animal (cat.) | Rat, In vitro | — | — | — | — |
PK/PD Experiment | pharmacokinetic | — | — | — | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Zeprumetostat: First Approval.. Zeprumetostat (), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd for the treatment of solid and haematological malignancies. In August 2025, zeprumetostat received conditional approval in China for use in adult patients with relapsed or ref… | — | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Zeprumetostat: First Approval.. Zeprumetostat (), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd for the treatment of solid and haematological malignancies. In August 2025, zeprumetostat received conditional approval in China for use in adult patients with relapsed or ref… | — | — | — |
Clinical Selected reported efficacy | ORR 100% | — | — | — | — |
Clinical Reported ORR | 100.0% | — | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | — | — | — | — |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
Clinical Trial ref | NCT02611323 | — | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Zeprumetostat | Vincristine Sulfate Liposome | Vevoctadekin | Verapamil Hydrochloride |
Overview Company | Roche / Genentech | Sun Yat-sen University | M.D. Anderson Cancer Center | Simcha Therapeutics | Bristol-Myers Squibb |
Overview Modality | ADC | CGT | ANTIBODY | CGT | ADC |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | Mature T-cell and NK-cell Lymphoma | Recurrent Acute Lymphoblastic Leukemia; Recurrent Adult Lymphoblastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · Medium | Data Confidence · Low | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | Investigational | Investigational | Investigational | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | — | — | — | — |
Positioning Known limitation | resistance to POLA in vivo | — | — | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | — | — | — | — |
Technology Linker | linker, or payload that have limited their development | — | — | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | — | — | — | — |
MoA Biomarker | CD20 expression | — | — | — | — |
PK/PD Half-life | 12.2 h | — | — | — | 16 h |
PK/PD Species | Rat | — | — | — | — |
PK/PD Animal (cat.) | Rat, In vitro | — | — | — | — |
PK/PD Experiment | pharmacokinetic | — | — | — | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | — | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Zeprumetostat: First Approval.. Zeprumetostat (), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd for the treatment of solid and haematological malignancies. In August 2025, zeprumetostat received conditional approval in China for use in adult patients with relapsed or ref… | — | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Zeprumetostat: First Approval.. Zeprumetostat (), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd for the treatment of solid and haematological malignancies. In August 2025, zeprumetostat received conditional approval in China for use in adult patients with relapsed or ref… | — | — | — |
Clinical Selected reported efficacy | ORR 100% | — | — | — | — |
Clinical Reported ORR | 100.0% | — | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | — | — | — | — |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — | — | — | — |
Clinical Trial ref | NCT02611323 | — | — | — | — |
추천 비교
추천 비교